-
公开(公告)号：US11634498B2
公开(公告)日：2023-04-25
申请号：US16097437
申请日：2017-04-28
IPC分类号： C07K16/28 , C07K14/725 , C07K14/705 , C12N5/16 , A61K48/00 , C12N9/64 , C12N15/86 , A61P35/00 , A61K35/17
摘要： Aspects of the disclosure relate to chimeric antigen receptors (CARs) comprising an antigen binding domain (e.g., anti-TSHR), transmembrane domain (e.g., CD28), and a cytoplasmic domain (e.g., CD27, CD-137, etc.) and a safety mechanism comprising an inducible apoptosis trigger. In some aspects, the disclosure relates to use of the CARs in T cells, compositions, kits and methods for the treatment of thyroid cancers.
-
公开(公告)号：US20180193489A1
公开(公告)日：2018-07-12
申请号：US15741253
申请日：2016-07-01
CPC分类号： A61K48/0058 , A61P35/00 , C12N15/86 , C12N2750/14122 , C12N2750/14143 , C12N2830/008
摘要： Provided herein are nucleic acids, recombinant adeno-associated virus (rAAV) particles, and compositions, as well as methods of use thereof for transducing medullary thyroid carcinoma cells and in treatment of disease, such as medullary thyroid carcinoma. In some aspects, the nucleic acid comprises a truncated calcitonin promoter, which is optionally encapsidated within a rAAV particle. In other aspects, the rAAV particle is a rAAV particle having a mutation in a surface-exposed amino acid, such as tyrosine, threonine, or serine, that enhances transduction of the particle into medullary thyroid carcinoma cells.
-
公开(公告)号：US20220233719A1
公开(公告)日：2022-07-28
申请号：US17590557
申请日：2022-02-01
摘要： Provided herein are nucleic acids, recombinant adeno-associated virus (rAAV) particles, and compositions, as well as methods of use thereof for transducing medullary thyroid carcinoma cells and in treatment of disease, such as medullary thyroid carcinoma. In some aspects, the nucleic acid comprises a truncated calcitonin promoter, which is optionally encapsidated within a rAAV particle. In other aspects, the rAAV particle is a rAAV particle having a mutation in a surface-exposed amino acid, such as tyrosine, threonine, or serine, that enhances transduction of the particle into medullary thyroid carcinoma cells.
-
公开(公告)号：US11266748B2
公开(公告)日：2022-03-08
申请号：US15741253
申请日：2016-07-01
摘要： Provided herein are nucleic acids, recombinant adeno-associated virus (rAAV) particles, and compositions, as well as methods of use thereof for transducing medullary thyroid carcinoma cells and in treatment of disease, such as medullary thyroid carcinoma. In some aspects, the nucleic acid comprises a truncated calcitonin promoter, which is optionally encapsidated within a rAAV particle. In other aspects, the rAAV particle is a rAAV particle having a mutation in a surface-exposed amino acid, such as tyrosine, threonine, or serine, that enhances transduction of the particle into medullary thyroid carcinoma cells.
-
公开(公告)号：US20190153109A1
公开(公告)日：2019-05-23
申请号：US16097437
申请日：2017-04-28
IPC分类号： C07K16/28 , C07K14/705 , C07K14/725 , A61K35/17 , A61P35/00
摘要： Aspects of the disclosure relate to chimeric antigen receptors (CARs) comprising an antigen binding domain (e.g., anti-TSHR), transmembrane domain (e.g., CD28), and a cytoplasmic domain (e.g., CD27, CD-137, etc.) and a safety mechanism comprising an inducible apoptosis trigger. In some aspects, the disclosure relates to use of the CARs in T cells, compositions, kits and methods for the treatment of thyroid cancers.
-
公开(公告)号：US11926604B2
公开(公告)日：2024-03-12
申请号：US17054600
申请日：2019-05-10
发明人： Scott A. Rivkees
IPC分类号： C07D285/24 , A61P25/28
CPC分类号： C07D285/24 , A61P25/28
摘要： The invention is directed towards compounds, methods of stimulating myelination, stimulating proliferation of oligodendrocytes (OLs) or stimulating oligodendrocyte precursor cells and methods of treating diseases, disorders or symptoms thereof.
-
公开(公告)号：US20230295319A1
公开(公告)日：2023-09-21
申请号：US18178819
申请日：2023-03-06
IPC分类号： C07K16/28 , C12N5/16 , A61K48/00 , C12N9/64 , C12N15/86 , A61P35/00 , A61K35/17 , C07K14/725 , C07K14/705
CPC分类号： C07K16/2869 , A61K35/17 , A61K48/005 , A61P35/00 , C07K14/7051 , C07K14/70521 , C07K14/70596 , C12N5/16 , C12N9/6472 , C12N15/86 , C12Y304/22062 , C07K2317/24 , C07K2317/622 , C07K2317/73 , C07K2319/02 , C07K2319/03 , C07K2319/70 , C12N2740/16043
摘要： Aspects of the disclosure relate to chimeric antigen receptors (CARs) comprising an antigen binding domain (e.g., anti-TSHR), transmembrane domain (e.g., CD28), and a cytoplasmic domain (e.g., CD27, CD-137, etc.) and a safety mechanism comprising an inducible apoptosis trigger. In some aspects, the disclosure relates to use of the CARs in T cells, compositions, kits and methods for the treatment of thyroid cancers.
-
公开(公告)号：US20220227875A1
公开(公告)日：2022-07-21
申请号：US17615041
申请日：2020-05-29
发明人： Scott A. Rivkees , Arun Srivastava
摘要： Disclosed herein are compositions and methods for continuous AAV-based delivery of blocking anti-TSHR antibodies to a subject having a thyroid disease. The present disclosure is based, at least in part, on the realization that blocking anti-TSHR antibodies may be delivered in a continuous manner using rAAV, e.g., rAAVS, to effectively block the stimulating effects of TSAbs or TSH on TSHR, thereby blocking or reducing the synthesis of thyroid hormone. By blocking or reducing the synthesis of thyroid hormone, the presently described methods and compositions for rAAV-based delivery of blocking anti-TSHR antibodies (e.g., may be used to treat thyroid diseases, including Graves' disease, Graves' orbitopathy, and thyroid cancer without the requirement of repeated administrations.
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.018 秒)
